Please assess the completion status of the following clinical trial:

Trial Title: Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both sex~* Age \> 1 year~* Fever (axillary temp ≥ 37.5oC) or history of fever during the preceding 48 hours~* Uncomplicated Plasmodium vivax confirm by microscopic examination~* Asexual parasite ≥ 250/µL blood~* Absence of clinical condition that need hospitalization~* No history of allergy to antimalarial drug~* Not consuming antibiotic with antimalarial activity~Exclusion Criteria:~* Clinical features of severe malaria~* Severe malnutrition~* Recurrent vomiting~* Concomitant infection~* Pregnant (test for β-HCG in women of child bearing age)~* Lactating mother~* Move out from study area~* Not eligible to follow up during study period

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHP+PQ (Type: EXPERIMENTAL): Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
- AS-AQ +PQ (Type: ACTIVE_COMPARATOR): Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).